ArticleBMC cancer2026
3D transformer-based dose prediction in HDR brachytherapy for cervical cancer.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dose control in robot-assisted seed brachytherapy: challenges, current status, and future directions.Journal of robotic surgery · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundThe clinical process of high-dose-rate brachytherapy (HDRBT) is time-consuming and relies on user expertise and preference. Deep learning-based dose prediction can act as a quality assurance (QA) tool to identify suboptimal needle placement and enhance treatment planning efficiency in HDR interstitial brachytherapy. This study aims to introduce a 3D transformer-based deep learning method to automatically predict the dose distribution in HDR brachytherapy for cervical cancer.
methodsWe retrospectively analyzed 96 CT-based treatment plans from 24 patients with cervical cancer who underwent interstitial HDRBT with needle insertion. The transformer mechanism was integrated into a convolutional neural network (CNN) to capture long-distance characteristics and global information. The prediction performance was evaluated by the mean error of dose‒volume histogram metrics between clinical and predicted dose maps, gamma analysis, and the Dice similarity coefficient (DSC) of the 1–30 Gy isodose volumes.
resultsThe mean D90 and D95 errors for HRCTV were less than 0.1 Gy, and the mean D2cc for organs at risk (bladder, rectum, and bowel) was less than 0.6 Gy. The mean DSC of the 1–30 Gy isodose volume was 0.87. The 3D transformer-based CNN model can predict dose maps that are highly consistent with the clinical treatment plans.
conclusionsA novel 3D transformer-based deep learning model was successfully developed for dose prediction in HDR interstitial brachytherapy. This method can automatically generate accurate 3D dose distributions, exhibiting great clinical potential for improving treatment efficiency and standardizing brachytherapy treatment planning.
trial registrationNo. ZF2020-084.2; Oct 16, 2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.